OBJECTIVE: The purpose of this study was to examine whether longitudinally sampled maternal angiogenic concentrations predict preeclampsia. STUDY DESIGN: Plasma sFlt-1 and placental growth factor (PlGF) concentrations in healthy pregnant women were quantified at 10, 17, 25, and 35 weeks' gestation. Preeclampsia was diagnosed with criteria from the American College of Obstetricians and Gynecologists. RESULTS: In the first trimester, sensitivity/specificity for PlGF and sFlt-1 were 55/43% and 57/40%, respectively, and did not improve appreciably as the pregnancy progressed. Among pregnancies that later experienced preeclampsia, median PlGF was lower beginning in the second trimester, but sFlt-1 was not higher until the third trimester. Analyte positive predictive values approached 10% in the third trimester. Negative predictive values were >90% for the entire pregnancy. CONCLUSION: Prediction of preeclampsia in early pregnancy was not possible with the use of maternal angiogenic protein concentrations. Even in late pregnancy, positive predictive values were not useful clinically. Negative predictive values are similarly unlikely to prove useful as a tool with which to a rule out suspected disease.
OBJECTIVE: The purpose of this study was to examine whether longitudinally sampled maternal angiogenic concentrations predict preeclampsia. STUDY DESIGN: Plasma sFlt-1 and placental growth factor (PlGF) concentrations in healthy pregnant women were quantified at 10, 17, 25, and 35 weeks' gestation. Preeclampsia was diagnosed with criteria from the American College of Obstetricians and Gynecologists. RESULTS: In the first trimester, sensitivity/specificity for PlGF and sFlt-1 were 55/43% and 57/40%, respectively, and did not improve appreciably as the pregnancy progressed. Among pregnancies that later experienced preeclampsia, median PlGF was lower beginning in the second trimester, but sFlt-1 was not higher until the third trimester. Analyte positive predictive values approached 10% in the third trimester. Negative predictive values were >90% for the entire pregnancy. CONCLUSION: Prediction of preeclampsia in early pregnancy was not possible with the use of maternal angiogenic protein concentrations. Even in late pregnancy, positive predictive values were not useful clinically. Negative predictive values are similarly unlikely to prove useful as a tool with which to a rule out suspected disease.
Authors: Ebony Boyce Carter; Jennifer J Stuart; Leslie V Farland; Janet W Rich-Edwards; Chloe A Zera; Thomas F McElrath; Ellen W Seely Journal: J Womens Health (Larchmt) Date: 2015-05-20 Impact factor: 2.681
Authors: Jeremy A Sandgren; Sabrina M Scroggins; Donna A Santillan; Eric J Devor; Katherine N Gibson-Corley; Gary L Pierce; Curt D Sigmund; Mark K Santillan; Justin L Grobe Journal: Am J Physiol Regul Integr Comp Physiol Date: 2015-03-25 Impact factor: 3.619
Authors: Amira M Aker; Lauren Johns; Thomas F McElrath; David E Cantonwine; Bhramar Mukherjee; John D Meeker Journal: Environ Int Date: 2018-02-01 Impact factor: 9.621
Authors: Anne Marie Darling; Martha M Werler; David E Cantonwine; Wafaie W Fawzi; Thomas F McElrath Journal: Epidemiology Date: 2019-09 Impact factor: 4.822
Authors: Lauren E Johns; Kelly K Ferguson; David E Cantonwine; Bhramar Mukherjee; John D Meeker; Thomas F McElrath Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach Journal: Geburtshilfe Frauenheilkd Date: 2015-09 Impact factor: 2.915